<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02547779</url>
  </required_header>
  <id_info>
    <org_study_id>IRB# 141349</org_study_id>
    <nct_id>NCT02547779</nct_id>
  </id_info>
  <brief_title>Isotonic Solutions and Major Adverse Renal Events Trial in the Non-Medical Intensive Care Unit (SMART-SURG)</brief_title>
  <acronym>SMART-SURG</acronym>
  <official_title>Isotonic Solutions and Major Adverse Renal Events Trial in Non-Medical Intensive Care Units</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The administration of intravenous fluids is ubiquitous in the care of the critically ill.
      Commonly available isotonic crystalloid solutions contain a broad spectrum electrolyte
      compositions including a range chloride concentrations. Recent studies have associated
      solutions with supraphysiologic chloride content with hyperchloremia, metabolic acidosis and
      renal vasoconstriction, acute kidney injury and renal replacement therapy, and increased
      mortality but no large, randomized-controlled trials have been conducted. SMART-SURG will be
      a large, cluster-randomized, multiple-crossover trial enrolling critically ill patients from
      the non-medical ICUs at Vanderbilt University from October 2015 until April 2017. The primary
      endpoint will be the incidence of Major Adverse Kidney Events in 30 days after enrollment
      (MAKE30 is the composite of death, new renal replacement, or persistent renal dysfunction at
      discharge).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SMART-SURG is a large, cluster-randomized, multiple-crossover trial of 0.9% saline versus
      physiologically-balanced isotonic crystalloids (Lactated Ringers or Plasma-Lyte© A) with
      regard to the incidence of major adverse kidney events by 30 days in patients admitted to
      non-medical intensive care units. All patients admitted to participating non-medical
      intensive care units at Vanderbilt University medical center who are 18 years or older will
      be enrolled. The study will occur in one-month blocks. Each participating ICU will be
      randomized to an initial fluid group (0.9% saline or physiologically balanced isotonic
      crystalloids). The assigned fluid will be used exclusively for all patients receiving
      isotonic crystalloid for the duration of the month-long block (except in the presence of
      pre-specified contraindications). The assigned study fluid will switch at the end of each
      month-long block such that half of the months are assigned to 0.9% saline and half of the
      months to physiologically balance fluid. The primary endpoint will be major adverse kidney
      events by 30 days (MAKE30 is the composite of death, new renal replacement therapy, or
      persistent renal dysfunction at discharge). All aspects of study design, intervention, and
      data collection will be harmonized with an ongoing, independent study addressing the same
      question in the medical intensive care unit at Vanderbilt University during a similar study
      period (SMART-MED). A pre-specified data analysis plan will dictate the harmonized analysis
      of SMART-MED and SMART-SURG.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2015</start_date>
  <completion_date type="Actual">June 30, 2017</completion_date>
  <primary_completion_date type="Actual">June 30, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Kidney Event Within 30 Days</measure>
    <time_frame>30 days after enrollment censored at hospital discharge</time_frame>
    <description>The primary outcome was the proportion of patients who met one or more criteria for a major adverse kidney event within 30 days — the composite of death, new receipt of renal-replacement therapy, or persistent renal dysfunction (defined as a final inpatient creatinine value ≥200% of the baseline value) — all censored at hospital discharge or 30 days after enrollment, whichever came first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>30-day In-hospital Mortality</measure>
    <time_frame>30 days after enrollment censored at hospital discharge</time_frame>
    <description>Death before hospital discharge, censored at 30 days after enrollment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10421</enrollment>
  <condition>Critical Illness</condition>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>0.9% Saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive 0.9% Saline whenever isotonic intravenous fluid administration is ordered by the treating provider.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Physiologically-balanced</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive Plasma-Lyte© A or Lactated Ringer's whenever isotonic intravenous fluid administration is ordered by the treating provider.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>0.9% Saline</intervention_name>
    <description>0.9% Saline will be used whenever an isotonic crystalloid is ordered</description>
    <arm_group_label>0.9% Saline</arm_group_label>
    <other_name>Normal Saline</other_name>
    <other_name>0.9% sodium chloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physiologically-balanced isotonic crystalloid</intervention_name>
    <description>Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered</description>
    <arm_group_label>Physiologically-balanced</arm_group_label>
    <other_name>Lactated Ringers</other_name>
    <other_name>Ringer's Lactate</other_name>
    <other_name>Plasma-Lyte© A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admitted to a participating non-medical intensive care unit (ICU) at Vanderbilt
             University Medical Center

        Exclusion Criteria:

          -  Age&lt;18 years old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd W Rice, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-2358</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Finfer S, Liu B, Taylor C, Bellomo R, Billot L, Cook D, Du B, McArthur C, Myburgh J; SAFE TRIPS Investigators. Resuscitation fluid use in critically ill adults: an international cross-sectional study in 391 intensive care units. Crit Care. 2010;14(5):R185. doi: 10.1186/cc9293. Epub 2010 Oct 15.</citation>
    <PMID>20950434</PMID>
  </reference>
  <reference>
    <citation>Yunos NM, Kim IB, Bellomo R, Bailey M, Ho L, Story D, Gutteridge GA, Hart GK. The biochemical effects of restricting chloride-rich fluids in intensive care. Crit Care Med. 2011 Nov;39(11):2419-24. doi: 10.1097/CCM.0b013e31822571e5.</citation>
    <PMID>21705897</PMID>
  </reference>
  <reference>
    <citation>Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M. Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA. 2012 Oct 17;308(15):1566-72. doi: 10.1001/jama.2012.13356.</citation>
    <PMID>23073953</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 9, 2015</study_first_submitted>
  <study_first_submitted_qc>September 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2015</study_first_posted>
  <results_first_submitted>August 19, 2019</results_first_submitted>
  <results_first_submitted_qc>November 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 25, 2019</results_first_posted>
  <last_update_submitted>November 5, 2019</last_update_submitted>
  <last_update_submitted_qc>November 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Todd Rice</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>crystalloid</keyword>
  <keyword>acute kidney injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasma-lyte 148</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT02547779/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The Isotonic Solutions and Major Adverse Events Trial (SMART) was registered for the medical ICU (NCT02444988), which enrolled 5381 patient beginning on June 1 2015, and then for the surgical ICUs (NCT02547779), which enrolled 10,421 patients beginning on October 1 2015. The overall SMART trial enrolled 15,802 patients and ended on April 30 2017.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>0.9% Sodium Chloride</title>
          <description>Patients in an ICU block randomized to saline will receive 0.9% sodium chloride whenever isotonic intravenous crystalloid administration is ordered by the treating provider.
Saline: 0.9% sodium chloride will be used whenever an isotonic crystalloid is ordered</description>
        </group>
        <group group_id="P2">
          <title>Balanced Crystalloids</title>
          <description>Patients in an ICU block randomized to balanced crystalloids will receive Plasma-Lyte A or Lactated Ringer's whenever isotonic intravenous crystalloid administration is ordered by the treating provider.
Balanced crystalloid: Lactated Ringers or Plasma-Lyte A will be used whenever an isotonic crystalloid is ordered</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5214"/>
                <participants group_id="P2" count="5207"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5214"/>
                <participants group_id="P2" count="5207"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>0.9% Sodium Chloride</title>
          <description>Patients in an ICU block randomized to saline will receive 0.9% sodium chloride whenever isotonic intravenous crystalloid administration is ordered by the treating provider.
Saline: 0.9% sodium chloride will be used whenever an isotonic crystalloid is ordered</description>
        </group>
        <group group_id="B2">
          <title>Balanced Crystalloids</title>
          <description>Patients in an ICU block randomized to balanced crystalloids will receive Plasma-Lyte A or Lactated Ringer's whenever isotonic intravenous crystalloid administration is ordered by the treating provider.
Balanced crystalloid: Lactated Ringers or Plasma-Lyte A will be used whenever an isotonic crystalloid is ordered</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5214"/>
            <count group_id="B2" value="5207"/>
            <count group_id="B3" value="10421"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="44" upper_limit="69"/>
                    <measurement group_id="B2" value="57" lower_limit="44" upper_limit="69"/>
                    <measurement group_id="B3" value="57" lower_limit="44" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2052"/>
                    <measurement group_id="B2" value="2108"/>
                    <measurement group_id="B3" value="4160"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3162"/>
                    <measurement group_id="B2" value="3099"/>
                    <measurement group_id="B3" value="6261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4344"/>
                    <measurement group_id="B2" value="4352"/>
                    <measurement group_id="B3" value="8696"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="870"/>
                    <measurement group_id="B2" value="855"/>
                    <measurement group_id="B3" value="1725"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Major Adverse Kidney Event Within 30 Days</title>
        <description>The primary outcome was the proportion of patients who met one or more criteria for a major adverse kidney event within 30 days — the composite of death, new receipt of renal-replacement therapy, or persistent renal dysfunction (defined as a final inpatient creatinine value ≥200% of the baseline value) — all censored at hospital discharge or 30 days after enrollment, whichever came first.</description>
        <time_frame>30 days after enrollment censored at hospital discharge</time_frame>
        <population>Of 15,802 patients in the SMART trial, 7,860 were assigned to saline and 7,942 were assigned to balanced crystalloids, of whom 10,421 were enrolled to surgical ICUs with 5,214 assigned to saline and 5,207 assigned to balanced crystalloids.</population>
        <group_list>
          <group group_id="O1">
            <title>0.9% Sodium Chloride</title>
            <description>Patients in an ICU block randomized to saline will receive 0.9% sodium chloride whenever isotonic intravenous crystalloid administration is ordered by the treating provider.
Saline: 0.9% sodium chloride will be used whenever an isotonic crystalloid is ordered</description>
          </group>
          <group group_id="O2">
            <title>Balanced Crystalloids</title>
            <description>Patients in an ICU block randomized to balanced crystalloids will receive Plasma-Lyte A or Lactated Ringer's whenever isotonic intravenous crystalloid administration is ordered by the treating provider.
Balanced crystalloid: Lactated Ringers or Plasma-Lyte A will be used whenever an isotonic crystalloid is ordered</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Kidney Event Within 30 Days</title>
          <description>The primary outcome was the proportion of patients who met one or more criteria for a major adverse kidney event within 30 days — the composite of death, new receipt of renal-replacement therapy, or persistent renal dysfunction (defined as a final inpatient creatinine value ≥200% of the baseline value) — all censored at hospital discharge or 30 days after enrollment, whichever came first.</description>
          <population>Of 15,802 patients in the SMART trial, 7,860 were assigned to saline and 7,942 were assigned to balanced crystalloids, of whom 10,421 were enrolled to surgical ICUs with 5,214 assigned to saline and 5,207 assigned to balanced crystalloids.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5214"/>
                <count group_id="O2" value="5207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="551"/>
                    <measurement group_id="O2" value="524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.95</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>30-day In-hospital Mortality</title>
        <description>Death before hospital discharge, censored at 30 days after enrollment</description>
        <time_frame>30 days after enrollment censored at hospital discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.9% Sodium Chloride</title>
            <description>Patients in an ICU block randomized to saline will receive 0.9% sodium chloride whenever isotonic intravenous crystalloid administration is ordered by the treating provider.
Saline: 0.9% sodium chloride will be used whenever an isotonic crystalloid is ordered</description>
          </group>
          <group group_id="O2">
            <title>Balanced Crystalloids</title>
            <description>Patients in an ICU block randomized to balanced crystalloids will receive Plasma-Lyte A or Lactated Ringer's whenever isotonic intravenous crystalloid administration is ordered by the treating provider.
Balanced crystalloid: Lactated Ringers or Plasma-Lyte A will be used whenever an isotonic crystalloid is ordered</description>
          </group>
        </group_list>
        <measure>
          <title>30-day In-hospital Mortality</title>
          <description>Death before hospital discharge, censored at 30 days after enrollment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5214"/>
                <count group_id="O2" value="5207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="408"/>
                    <measurement group_id="O2" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.98</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <desc>An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered an intervention that does not necessarily have to have a causal relationship with this treatment. An adverse event therefore can be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an intervention, whether or not the incident is considered to be related to the intervention.</desc>
      <group_list>
        <group group_id="E1">
          <title>0.9% Sodium Chloride</title>
          <description>Patients in an ICU block randomized to saline will receive 0.9% sodium chloride whenever isotonic intravenous crystalloid administration is ordered by the treating provider.
Saline: 0.9% sodium chloride will be used whenever an isotonic crystalloid is ordered</description>
        </group>
        <group group_id="E2">
          <title>Balanced Crystalloids</title>
          <description>Patients in an ICU block randomized to balanced crystalloids will receive Plasma-Lyte A or Lactated Ringer's whenever isotonic intravenous crystalloid administration is ordered by the treating provider.
Balanced crystalloid: Lactated Ringers or Plasma-Lyte A will be used whenever an isotonic crystalloid is ordered</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="408" subjects_at_risk="5214"/>
                <counts group_id="E2" subjects_affected="400" subjects_at_risk="5207"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5207"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse Event</sub_title>
                <description>Patient received Plasma-Lyte A® as post-filter replacement fluid during continuous RRT instead of 0.9% sodium chloride. The patient experience no significant changes in heart rate, systolic blood pressure, vasopressors, electrolytes or acid-base.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5214"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5207"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Matthew W. Semler, MD, MSc</name_or_title>
      <organization>VANDERBILT UNIVERSITY MEDICAL CENTER</organization>
      <phone>(615) 322-3412</phone>
      <email>matthew.w.semler@vumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

